Platelet proteomic profiling in sitosterolemia suggests thrombocytopenia is driven by lipid disorder and not platelet aberrations
Blood Adv. 2024 Mar 21:bloodadvances.2023012018. doi: 10.1182/bloodadvances.2023012018. Online ahead of print.ABSTRACTSitosterolemia is a rare autosomal-recessive genetic disorder in which patients develop hypercholesterolemia, and may exhibit abnormal hematologic and/or liver test results. In this disease, dysfunction of either ABCG5 or ABCG8 results in intestinal hyperabsorption of all sterols, including cholesterol and more specifically plant sterols or xenosterols, as well as in the impaired ability to excrete xenosterols into the bile. It remains unknown how and why some patients develop hematologic abnormalities. Onl...
Source: Adv Data - March 21, 2024 Category: Epidemiology Authors: Jessica Del Castillo Alferez Anton T J Tool Karin van Leeuwen Floris P J van Alphen Marion M Brands Monique H Suijker Alexander B Meijer Arie J Hoogendijk Taco W Kuijpers Source Type: research
Diagnosis and treatment of elevated lipoprotein(a) in israel: consensus statement from the israel society for research, prevention and treatment of atherosclerosis and israel society for clinical laboratory sciences
Harefuah. 2024 Mar;163(3):185-190.ABSTRACTLipoprotein(a) [Lp(a)] is composed of 2 major protein components, a low-density lipoprotein (LDL) cholesterol-like particle containing apolipoprotein B (apo B) that is covalently bound to apolipoprotein(a). Its level is predominantly genetically determined, and it is estimated that 20% to 25% of the population have Lp(a) levels that are associated with increased cardiovascular risk. Elevated Lp(a) is related to increased vascular inflammation, calcification, atherogenesis and thrombosis, and is considered an independent and potentially causal risk factor for atherosclerotic cardiov...
Source: Atherosclerosis - March 20, 2024 Category: Cardiology Authors: Barak Zafrir Ronen Durst Clara Henig Yaakov Henkin Elena Itzhakov Marielle Kaplan Dov Gavish Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Diagnosis and treatment of elevated lipoprotein(a) in israel: consensus statement from the israel society for research, prevention and treatment of atherosclerosis and israel society for clinical laboratory sciences
Harefuah. 2024 Mar;163(3):185-190.ABSTRACTLipoprotein(a) [Lp(a)] is composed of 2 major protein components, a low-density lipoprotein (LDL) cholesterol-like particle containing apolipoprotein B (apo B) that is covalently bound to apolipoprotein(a). Its level is predominantly genetically determined, and it is estimated that 20% to 25% of the population have Lp(a) levels that are associated with increased cardiovascular risk. Elevated Lp(a) is related to increased vascular inflammation, calcification, atherogenesis and thrombosis, and is considered an independent and potentially causal risk factor for atherosclerotic cardiov...
Source: Atherosclerosis - March 20, 2024 Category: Cardiology Authors: Barak Zafrir Ronen Durst Clara Henig Yaakov Henkin Elena Itzhakov Marielle Kaplan Dov Gavish Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population
CONCLUSION AND RELEVANCE: Low-intensity statin plus ezetimibe may be an alternative to moderate-intensity statin for primary prevention. Our findings provide evidence on safety and efficacy of statin therapy in Asian population.PMID:38506414 | DOI:10.1177/10600280241237781 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - March 20, 2024 Category: Drugs & Pharmacology Authors: Minji Jung Beom-Jin Lee Sukhyang Lee Jaekyu Shin Source Type: research
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
ConclusionsTargeting dyslipidemia in NENs should be part of the multidisciplinary management and an integrated approach may be the best option for both metabolic and tumor control. Whether lipid lowering agents may directly contribute to tumor control remains to be confirmed with specific studies, focusing on association with other metabolic risk, disease stage and primary site. (Source: Endocrine)
Source: Endocrine - March 20, 2024 Category: Endocrinology Source Type: research
Importance of Considering Fed-State Gastrointestinal Physiology in Predicting the Reabsorption of Enterohepatic Circulation of Drugs
ConclusionFor drugs which undergo EHC and can be solubilized by bile micelles, compensating for the permeation rate constant in the reabsorption process based on the free fraction ratio appears an important factor in increasing the accuracy of PK profile prediction. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - March 12, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan
CONCLUSIONS: This study provides real-world insights into evolocumab utilization in Japan for optimizing patient care and adherence to guideline-based therapies to better address hypercholesterolemia in Japan.PMID:38432948 | DOI:10.1253/circj.CJ-23-0814 (Source: Circulation Journal)
Source: Circulation Journal - March 3, 2024 Category: Cardiology Authors: Feng Sheng Alex Y Wang Kazumasa Miyawaki Takahiro Tsuchiya Nobuhiro Osada Russell Miller Ziyang Fu Tomonori Okamura Source Type: research
Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan
CONCLUSIONS: This study provides real-world insights into evolocumab utilization in Japan for optimizing patient care and adherence to guideline-based therapies to better address hypercholesterolemia in Japan.PMID:38432948 | DOI:10.1253/circj.CJ-23-0814 (Source: Circulation Journal)
Source: Circulation Journal - March 3, 2024 Category: Cardiology Authors: Feng Sheng Alex Y Wang Kazumasa Miyawaki Takahiro Tsuchiya Nobuhiro Osada Russell Miller Ziyang Fu Tomonori Okamura Source Type: research
